Bueno Cristiane Schmalz, Moreira Angélica Cristiane, Oliveira Karla Renata de
Departamento de Ciências da Saúde, Universidade Regional do Noroeste do Estado do Rio Grande do Sul, Ijuí, RS, Brasil.
Rev Panam Salud Publica. 2012 Jan;31(1):62-7. doi: 10.1590/s1020-49892012000100009.
Diseases of the circulatory system are a principal cause of mortality in Brazil. Using as a basis drugs dispensed through Brazil's Popular Pharmacy Program (FPB, for its name in Portuguese), prices for drugs used to treat circulatory diseases were analyzed to identify the advantages of using generic drugs and the FPB.
Drug prices were obtained using Brazil's Pharmacy Price Guide and FPB price tables. The costs of 15 drugs available through the FPB were compared with those of three generic pharmaceutical products, three similar products, and the reference drug.
The generic drugs were lower in price for 10 of the drugs and for four of the similar products. The FPB drugs were of the lowest price.
Generic and FPB drugs are easily accessed by the population and thus facilitate the continuity of pharmacotherapy when these drugs are not available through the Unified Health System and/or are not affordable through other means. Access to drugs should be taken into consideration at the time prescriptions are filled, especially as regards those used to treat chronic diseases.
循环系统疾病是巴西主要的死亡原因。以巴西大众药房计划（葡萄牙语缩写为FPB）所配药物为基础，分析用于治疗循环系统疾病的药物价格，以确定使用仿制药和大众药房计划的优势。
利用巴西药房价格指南和大众药房计划价格表获取药品价格。将通过大众药房计划可获得的15种药物的成本与三种仿制药产品、三种类似产品以及参比药品的成本进行比较。
10种药物和4种类似产品的仿制药价格较低。大众药房计划的药物价格最低。
当这些药物无法通过统一卫生系统获得和/或无法通过其他方式负担得起时，仿制药和大众药房计划的药物很容易被民众获取，从而有助于药物治疗的连续性。在开处方时应考虑药物的可及性，尤其是对于用于治疗慢性病的药物。
